{"product_id":"global-genomics-partnering-terms-and-agreements-2016-to-2023","title":"Global Genomics Partnering Terms and Agreements 2016 to 2023","description":"\u003cp\u003eGlobal Genomics Partnering Terms and Agreements 2016 to 2023\u003cbr\u003e\nThe Global Genomics Partnering Terms and Agreements 2016 to 2023 report provides an understanding and access to the genomics partnering deals and agreements entered into by the worlds leading healthcare companies.\u003c\/p\u003e\n\n\u003cp\u003eTrends in genomics partnering deals\u003cbr\u003e\nDisclosed headlines, upfronts, milestones and royalties by stage of development\u003cbr\u003e\nGenomics partnering contract documents\u003cbr\u003e\nTop genomics deals by value\u003c\/p\u003e\n\n\u003cp\u003eThe Global Genomics Partnering Terms and Agreements report provides an understanding and access to the genomics partnering deals and agreements entered into by the worlds leading healthcare companies.\u003c\/p\u003e\n\n\u003cp\u003eThe report provides a detailed understanding and analysis of how and why companies enter genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R\u0026amp;D, and commercialization of outcomes.\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.\u003c\/p\u003e\n\n\u003cp\u003eThis report contains links to online copies of actual genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.\u003c\/p\u003e\n\n\u003cp\u003eContract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.\u003c\/p\u003e\n\n\u003cp\u003eFor example, analyzing actual company deals and agreements allows assessment of the following:\u003c\/p\u003e\n\n\u003cp\u003eWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in genomics dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 provides a review of the leading genomics deals since 2016. Deals are listed by headline value, signed by big pharma, most active genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides a comprehensive listing of the top 25 most active companies in genomics dealmaking with a brief summary followed by a comprehensive listing of genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R\u0026amp;D, co-promotion, licensing etc), and specific therapy focus.\u003c\/p\u003e\n\n\u003cp\u003eChapter 6 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomics technology type in focus.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, a comprehensive appendix is provided organized by genomics partnering company A-Z, deal type definitions and genomics partnering agreements example.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous tables and figures that illustrate the trends and activities in genomics partnering and dealmaking since 2016.\u003c\/p\u003e\n\n\u003cp\u003eIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genomics technologies and products.\u003c\/p\u003e\n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eGlobal Genomics Partnering Terms and Agreements 2016 to 2023  is intended to provide the reader with an in-depth understanding and access to genomics trends and structure of deals entered into by leading companies worldwide.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Genomics Partnering Terms and Agreements 2016 to 2023 includes:\u003c\/p\u003e\n\n\u003cp\u003eTrends in genomics dealmaking in the biopharma industry since 2016\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nAccess to over 800 genomics deal records and contract documents where available\u003cbr\u003e\nThe leading genomics deals by value since 2016\u003cbr\u003e\nMost active genomics dealmakers since 2016\u003cbr\u003e\nThe leading genomics partnering resources\u003c\/p\u003e\n\n \u003cp\u003eIn Global Genomics Partnering Terms and Agreements 2016 to 2023, the available contracts are listed by:\u003c\/p\u003e\n\n\u003cp\u003eCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nStage of development at signing\u003cbr\u003e\nDeal component type\u003cbr\u003e\nSpecific therapy and technology target\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 450 Pages \/ MCW16230274","offer_id":47647062917426,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-genomics-partnering-terms-and-agreements-2016-to-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}